Jun-2024
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Stigma Grow has shown a strong performance in the Capsules category across various provinces, particularly in Alberta. In Alberta, they maintained the top position from March to May 2024 before slipping to second place in June 2024. Despite this slight drop, their sales figures demonstrate a consistent demand, even though there was a noticeable decline from March to June. In British Columbia, Stigma Grow has fluctuated in the Capsules category, ranking sixth in March, dropping to ninth in April and May, and slightly improving to seventh in June. This indicates a competitive market in British Columbia where Stigma Grow is holding its ground but faces stiff competition. Meanwhile, in Ontario, the brand has maintained a steady ninth position throughout the months, reflecting a stable yet unremarkable presence in that market.
The performance in the Concentrates category presents a more varied picture. In Alberta, Stigma Grow has seen some positive movement, improving from the 16th position in March to 15th in April, then slipping back to 17th in May, but recovering to 15th again in June. This fluctuation suggests a volatile market where Stigma Grow is striving to improve its standing. Conversely, in British Columbia, the brand has shown a positive trend, moving from 26th place in March to 18th in April, and maintaining a position within the top 20 through June. However, the fact that Stigma Grow did not rank in the top 30 in some months in certain categories indicates areas where the brand could potentially focus on improving its market penetration and competitive strategy.
Competitive Landscape
In the Alberta capsules category, Stigma Grow has shown a notable shift in its competitive positioning over recent months. Initially holding the top rank in March, April, and May 2024, Stigma Grow experienced a slight decline to the second position in June 2024. This change coincided with a consistent increase in sales for Glacial Gold, which rose to the first position in June. Meanwhile, Dosecann maintained a steady fourth position throughout the period, and Ovis showed a significant improvement, climbing from seventh in March to third in June. These shifts indicate a dynamic market where Stigma Grow faces increasing competition, particularly from Glacial Gold, which has shown strong upward momentum in both rank and sales.
Notable Products
In June 2024, the top-performing product for Stigma Grow was Indica RSO Capsules 25-Pack (250mg) in the Capsules category, maintaining its number one rank consistently from March to June, with sales of 6,271 units. Phoenix Tears RSO (1g) in the Concentrates category also held steady in the second position throughout the same period, showing a notable increase in sales to 3,154 units. CBD Softgels 15-Pack (750mg CBD) in the Capsules category consistently ranked third from March to June, with a gradual increase in sales each month. The Ghost Train Haze Infused Pre-Roll (0.5g) debuted at rank four in May 2024 and maintained this position in June. Lastly, Phoenix Tears Honey Oil (1g), another Concentrates product, reappeared in the rankings at fifth place in June after not being ranked in April and May.